Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update

Key Takeaways

• Cutting speed raised to 25,000 cuts per minute
• Flow rate improves 25% for faster vitreous removal
• Adaptive Fluidics stabilizes intra‑ocular pressure during surgery
• Cutter vibration reduced 62% enhancing surgeon comfort
• Dual‑port design maintains 100% duty cycle, improving efficiency

Pulse Analysis

The FDA’s 510(k) approval of Bausch + Lomb’s Bi‑Blade™+ cutter marks a notable step forward in vitreoretinal surgery technology. By pushing cutting speeds to 25,000 cuts per minute, the device minimizes retinal traction and accelerates vitreous removal, addressing a long‑standing challenge for surgeons who balance speed with tissue safety. The dual‑port architecture preserves a 100% duty cycle, ensuring continuous aspiration and reducing the need for manual adjustments during delicate maneuvers.

Beyond raw speed, the integration of Adaptive Fluidics delivers real‑time infusion control that reacts to vacuum changes, keeping intra‑ocular pressure within a physiologic 10‑20 mmHg window even under high vacuum settings. Clinical data show a 62% drop in infusion pressure variability and cutter vibration, translating to smoother instrument handling and potentially fewer postoperative complications. These performance gains can shorten operative times, lower anesthesia exposure, and improve overall patient recovery trajectories.

For the ophthalmic device market, Bausch + Lomb’s clearance reinforces its position as an innovator amid growing competition from European and Asian manufacturers. The combined hardware and software upgrade not only expands the Stellaris Elite platform’s value proposition but also creates a compelling upgrade path for existing users. As retinal surgeons increasingly demand precision and efficiency, the Bi‑Blade™+ system is poised to capture market share and set a new benchmark for next‑generation vitrectomy solutions.